Business
HOTH THERAPEUTICS ACCELERATES HT-001 TRIAL ENROLLMENT WITH NEW CLINICAL SITE AS PATIENT DEMAND INCREASES
Hoth Therapeutics, Inc. (NASDAQ: HOTH) today announced a significant expansion of its CLEER-001 Phase 2a clinical trial with the addition of Regis Clinical Research as a new enrolling site. Located in Miami, Florida, Regis joins the growing CLEER-001 investigational site network as surging patient demand outpaces capacity at existing sites — a direct reflection of the compelling early clinical results HT-001 has produced and the desperate unmet need it addresses.
About this update from Hoth Therapeutics, Inc.
[{"type":"text","content":"CLEER-001 Phase 2a Expansion Signals Growing Momentum Behind First-in-Class Therapy for Cancer Patients With No Current FDA-Approved Treatment Option","length":149,"tagName":"p","attribs":{}},{"type":"text","content":"NEW YORK, Feb. 24, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) today announced a significant expansion of its CLEER-001 Phase 2a clinical trial with the addition of Regis Clinical Research as a new enrolling site. Located in Miami, Florida, Regis joins the growing CLEER-001 investigational site network as surging patient demand outpaces capacity at existing sites — a direct reflection of the compelling early clinical results HT-001 has produced and the desperate unmet need it addresses.","length":517,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Hoth Therapeutics Inc.)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Hoth Therapeutics Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":68,"url":"https://media.zenfs.com/en/prnewswire.com/a168928171a9653a66d38f6c5e666beb"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/r2Ptel_Ut1tf_dA2SUFY0g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTEyMDtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/a168928171a9653a66d38f6c5e666beb","width":400,"height":68}},"href":"https://mma.prnewswire.com/media/644804/Hoth_Therapeutics_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"For the estimated 200,000 Americans who begin EGFR Inhibitor cancer therapy each year, the skin toxicities that accompany treatment are not a minor inconvenience. They are severe, often disfiguring rashes, lesions, and unrelenting itch that force up to one-third of patients to reduce or discontinue the chemotherapy keeping them alive. Today, those patients have no FDA-approved treatment option. HT-001 is designed to change that — and the data so far suggests it can.","length":470,"tagName":"p"},{"type":"text","content":"Positive Signal","length":15,"tagName":"p"},{"type":"text","content":"The interim CLEER-001 data is generating physician and patient interest that drives enrollment expansions like today's announcement:","length":141,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"100% of open-label cohort patients achieved the primary efficacy endpoint — an ARIGA rash severity ...